News | December 23, 2021
Evusheld neutralises Omicron in latest studies
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research
Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorised in the US to prevent Covid-19
The recommendation was made by the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG), a network of national testing labs set up by the government to monitor genomic variations of Covid-19
The UK’s Medicine and Healthcare products Regulatory Agency has already approved the booster dose of AstraZenenca’s Covid-19 vaccine, which is administered in India
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
The interim data combines three mRNAs into one therapy injected directly into the tumour
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
Subscribe To Our Newsletter & Stay Updated
